Log In
BCIQ
Print this Print this
 

Emibetuzumab (LA480, LY2875358)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHumanized IgG4 mAb targeting c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today